Overview of Dr. Meyers
Dr. Paul Meyers is a pediatric hematologist/oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Icahn School of Medicine at Mount Sinai and has been in practice 44 years. He is one of 92 doctors at Memorial Sloan Kettering Cancer Center who specialize in Pediatric Hematology & Oncology. He also speaks multiple languages, including Spanish and French. He has more than 100 publications and over 500 citings.
Office
628 W 227th St
1275 York Avenue
New York, NY 10065- Is this information wrong?
Education & Training
- Memorial Hospital1978 - 1979
- Sloan-Kettering Institute1977 - 1979
- Cornell Medical Center1976 - 1976
- Mt Sinai Hospital1974 - 1976
- Mt Sinai Hospital1973 - 1974
- Icahn School of Medicine at Mount SinaiClass of 1973
- Brown UniversityAB, Cum laude, 1966 - 1971
Certifications & Licensure
- FL State Medical License 2022 - Present
- NY State Medical License 1974 - 2026
- NJ State Medical License 1982 - 2025
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- New York Magazine: Top Doctors Castle Connolly, 2002-2014
- America's Top Doctors Castle Connolly, 2002-2014
- Top Doctors: New York Metro Area Castle Connolly, 2002-2014
- Join now to see all
Clinical Trials
- Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor Start of enrollment: 1995 Apr 01
- Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma Start of enrollment: 1998 Sep 01
- Trastuzumab in Treating Patients With Recurrent Osteosarcoma Start of enrollment: 1999 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- Chromoplexy is a frequent early clonal event in EWSR1-rearranged round cell sarcomas that can be detected using clinically validated targeted sequencing panels.Healey, J., Vanoli, F., Vanderbilt, C., Dermawan, J., Slotkin, E., Tap, W., Meyers, P., Wexler, L., Antonescu, C.> ;Cancer Research. 2024 Feb 9
- 1 citationsIrinotecan dose schedule for the treatment of Ewing sarcoma.Emily K Slotkin, Paul A Meyers> ;Pediatric Blood & Cancer. 2023 Jan 1
- 11 citationsComprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor, , , , , , , , , , , , , , , , , , , , , , > ;Molecular Cancer Research. 2021 Mar 22
- Join now to see all
Journal Articles
- Prognostic factors for patients with sarcomas of the pelvic bones.Kawai A, Healey JH, Boland P, Lin PP, Huvos AG, Meyers PA, Cancer 1998; 82:851-9
- EWS-FLI1 Fusion transcript structure is an independent determinant of prognosis in Ewing’s sarcoma.de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, Gerald WE, Jhanwar SC, Agrani P, Antonexcu CR, Pardo-Mindan FJ, Ginsberg J, Womer R, Lawlor ER, Wunder ..., J Clin Onc 1998, 16:1248-1255
- Intensification of preoperative chemotherapy for osteogenic sarcoma: The results of the Memorial Sloan-Kettering (T12) protocol.Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG Healey JH, J Clin Onc 1998, 16:2452-2458
- Join now to see all
Books/Book Chapters
Lectures
- The addition of cycles of irinotecan/temozolomide (i/T) to cycles of vincristine, doxorubicin, cyclophosphamide (VDC) and cycles of ifosfamide, etoposide (IE) for the ...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Other
- High dose therapy with autologous stem cell rescue for pediatric sarcomas.Meyers PA, ASCO Education Book
- Holcombe Grier Faculty of 1000 Medicine: evaluations for Meyers PA et al.Paul A. Meyers, Cindy Schwartz, Mark Krailo, Eugenie Kleinerman, Donna Betcher, William Ferguson, Mark Gebhardt, Allen Goorin, Helen Nadel, Michael Nieder, Gene Sigel,..., J Clin Oncol 2008 Feb 1 26 (4) :633-8
http://www.f1000medicine.com/article/id/1100377/evaluation - Response to Osteosarcoma: Time to Move On?Meyers PA, Kleinerman E, European Journal of Cancer
http://www.ecco-org.eu/News/News/EJC-Correspondence/Latest-Correspondence/Osteosarcoma-Time-to-move-
Press Mentions
- Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, Its First-in-Class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual MeetingNovember 14th, 2019
- Oncternal Therapeutics Announces Presentation of Case Study of TK216 in Ewing Sarcoma Given at the Children’s Oncology Group MeetingNovember 5th, 2019
- Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children’s Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing SarcomaOctober 8th, 2019
Grant Support
- Core BNational Cancer Institute2005–2009
Professional Memberships
- Member
- Member
- American Society of Pediatric Hematology/OncologyMember
- Connective Tissue Oncology SocietyMember
Other Languages
- Spanish, French
Hospital Affiliations
- Memorial Sloan Kettering Cancer CenterNew York, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: